PL1532986T3 - Kompozycja farmaceutyczna do leczenia nieżytów nosa - Google Patents

Kompozycja farmaceutyczna do leczenia nieżytów nosa

Info

Publication number
PL1532986T3
PL1532986T3 PL04024727T PL04024727T PL1532986T3 PL 1532986 T3 PL1532986 T3 PL 1532986T3 PL 04024727 T PL04024727 T PL 04024727T PL 04024727 T PL04024727 T PL 04024727T PL 1532986 T3 PL1532986 T3 PL 1532986T3
Authority
PL
Poland
Prior art keywords
rhinitis
pharmaceutical composition
treatment
action
salts
Prior art date
Application number
PL04024727T
Other languages
English (en)
Inventor
Harald Greve
Rainer Greve
Original Assignee
Maria Clementine Martin Klosterfrau Vertriebsges Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maria Clementine Martin Klosterfrau Vertriebsges Mbh filed Critical Maria Clementine Martin Klosterfrau Vertriebsges Mbh
Publication of PL1532986T3 publication Critical patent/PL1532986T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04024727T 2003-11-13 2004-10-16 Kompozycja farmaceutyczna do leczenia nieżytów nosa PL1532986T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10353690 2003-11-13
DE10356248A DE10356248A1 (de) 2003-11-13 2003-12-02 Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
EP04024727A EP1532986B1 (de) 2003-11-13 2004-10-16 Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden

Publications (1)

Publication Number Publication Date
PL1532986T3 true PL1532986T3 (pl) 2010-05-31

Family

ID=31969799

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04024727T PL1532986T3 (pl) 2003-11-13 2004-10-16 Kompozycja farmaceutyczna do leczenia nieżytów nosa

Country Status (12)

Country Link
US (2) US20050107330A1 (pl)
EP (1) EP1532986B1 (pl)
JP (1) JP2005145963A (pl)
AT (1) ATE451934T1 (pl)
CY (1) CY1110289T1 (pl)
DE (3) DE10356248A1 (pl)
DK (1) DK1532986T3 (pl)
ES (1) ES2336668T3 (pl)
NO (1) NO333334B1 (pl)
PL (1) PL1532986T3 (pl)
PT (1) PT1532986E (pl)
SI (1) SI1532986T1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1507543A4 (en) * 2002-05-09 2006-07-26 Cambridgemed Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF WOOD WITH BLOOD PLASMA OR SERUM
US7323184B2 (en) 2005-08-22 2008-01-29 Healagenics, Inc. Compositions and methods for the treatment of wounds and the reduction of scar formation
DE102007052380A1 (de) 2007-10-31 2009-05-07 Bitop Ag Osmolythaltige Zubereitungen zur Anwendung bei trockenen Schleimhäuten
IT1396468B1 (it) * 2008-11-11 2012-12-14 Farma Derma Srl Uso topico di acido ialuronico ad azione filmogena in preparati per il trattamento e profilassi di patologie delle vie respiratorie.
WO2012119261A1 (en) * 2011-03-10 2012-09-13 Biocia Inc. Enhanced artificial mucus composition comprising hyaluronan for the treatment of rhinitis
LT2543357T (lt) 2011-07-07 2018-06-11 Holy Stone Healthcare Co.,Ltd. Kompozicija, skirta panaudoti su uždegimu susijusių susirgimų gydymui arba prevencijai
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
EP2723330B1 (de) * 2011-08-19 2015-07-08 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mbH Vasokonstriktorhaltiges kombinationstherapeutikum
DE102012005452A1 (de) * 2011-12-30 2013-07-04 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die nasale Applikation mit verbesserter Stabilität
DE202012005650U1 (de) 2012-05-14 2013-05-15 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Kombinationstherapeutikum für die Behandlung von Rhinitis
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
EP2985027B1 (en) 2014-08-16 2021-03-31 Church & Dwight Co., Inc. Nasal composition comprising mixture of hyaluronic acids and saline solution
DE102014116903A1 (de) 2014-08-18 2016-02-18 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Cineolhaltige Zusammensetzung für die nasale Applikation
DE202015104410U1 (de) 2015-07-06 2016-07-13 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Zusammensetzung für die Behandlung von Rhinitis
DE102015115107A1 (de) 2015-09-01 2017-03-02 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Cineolhaltige wässrige Zusammensetzung für die nasale Applikation
DE202017104738U1 (de) 2017-07-31 2018-08-01 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Neue Zusammensetzung für die nasale Applikation
WO2019125330A2 (en) * 2017-08-10 2019-06-27 Eli̇xi̇r İlaç Araştirma Ve Geli̇şti̇rme A.Ş. Nasal decongestant compositions comprising dexpanthenol and sodium hyaluronate
WO2023046590A1 (en) 2021-09-22 2023-03-30 Jadran - Galenski Laboratorij D.D. An improved pharmaceutical composition for nasal use, preparation, and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1087842A (en) 1963-05-01 1967-10-18 Leo Ab Nasal decongestive compositions
IL101056A (en) * 1992-02-24 1997-03-18 Res & Dev Co Ltd Composition for nasal treatment
JPH0717870A (ja) 1993-06-29 1995-01-20 Toshiko Yamamoto トローチ剤
US5631242A (en) * 1993-08-04 1997-05-20 Patent Biopharmaceutics, Inc. Hyaluronic acid-urea pharmaceutical compositions utilized for treatment of diseases of cutis
DE19549421C2 (de) 1995-11-10 1999-11-18 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE19541919C2 (de) * 1995-11-10 1997-11-20 Klosterfrau Mcm Vetrieb Gmbh Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
PT1997478E (pt) * 2001-02-15 2013-12-10 Access Pharma Inc Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
DE10161110A1 (de) 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
RU2005101331A (ru) * 2002-06-20 2006-01-20 Новартис Консьюмер Хелс С.А. (Ch) Назальная композиция, включающая мукополисахарид и пропиленгликоль

Also Published As

Publication number Publication date
PT1532986E (pt) 2010-02-18
SI1532986T1 (sl) 2010-04-30
US20110245202A1 (en) 2011-10-06
EP1532986A3 (de) 2005-07-20
DK1532986T3 (da) 2010-04-06
CY1110289T1 (el) 2015-01-14
ATE451934T1 (de) 2010-01-15
DE20318634U1 (de) 2004-02-26
EP1532986A2 (de) 2005-05-25
DE10356248A1 (de) 2005-06-23
ES2336668T3 (es) 2010-04-15
DE502004010514D1 (de) 2010-01-28
JP2005145963A (ja) 2005-06-09
US20050107330A1 (en) 2005-05-19
NO333334B1 (no) 2013-05-06
EP1532986B1 (de) 2009-12-16
HK1080284A1 (zh) 2006-04-21
NO20044639L (no) 2005-05-18

Similar Documents

Publication Publication Date Title
CY1110289T1 (el) Φαρμακευτικη συνθεση για τη θεραπεια ρινιτιδων
AU2002251009A1 (en) Tiotropium salts for treating inflammatory diseases
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
PT1333887E (pt) Metodo de tratamento de desordens musculares
ATE401865T1 (de) Orale darreichungsformen für propiverin oder seinen pharmazeutisch annehmbaren salzen mit verlängerter wirkstofffreisetzung
GB0031088D0 (en) Medicaments
GB0112836D0 (en) Medicaments
WO2003015779A3 (de) Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
PT946176E (pt) Utilizacao de derivados de acido 7-(2-oxa-5,8-diazabiciclo¬4.3.0|non-8-il)-quinolonacarboxilico e -naftiridonacarboxilico para terapia de infeccoes por helicobacter pylori e das doencas gastroduodenais a elas associadas
MXPA03010761A (es) Combinaciones farmaceuticas.
MA27566A1 (fr) Inhibiteurs de 4-oxo-1-(3-phenyle substitue -1, 4-dihydro-1, 8-naphthyridine-3-carboxamide phosphodiesterase-4
DE60205899D1 (en) 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
NO20050662L (no) COX-2 inhiberende pyridinderivater
EP1440691A3 (en) Treatment of neurotic disorders
WO2004002491A8 (en) Morpholine and tetrahydropyran drivatives and their use as cathepsin inhibitors
HRP20050439B1 (hr) Nova upotreba dekstran sulfata
PT1150704E (pt) Melagatran para o tratamento da inflamacao
DE60003289D1 (de) Kombinationstherapie für lymphoproliferative krankheiten
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
AU2003258630A1 (en) Pyrimidine derivatives as selective cox-2 inhibitors
EP1362590A8 (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
MXPA03003980A (es) Uso de melagatran para la elaboracion de un medicamento para el tratamiento de transtornos isquemicos.
DE602004002964D1 (de) 7-azaindolderivate als cox2-inhibitoren
AU2001285156A1 (en) Combination therapy for the treatment of migraine